NO990401L - Anvendelse av aminer for Õ fremstille legemidler for Õ forhindre tumorcelleproliferasjon - Google Patents

Anvendelse av aminer for Õ fremstille legemidler for Õ forhindre tumorcelleproliferasjon

Info

Publication number
NO990401L
NO990401L NO990401A NO990401A NO990401L NO 990401 L NO990401 L NO 990401L NO 990401 A NO990401 A NO 990401A NO 990401 A NO990401 A NO 990401A NO 990401 L NO990401 L NO 990401L
Authority
NO
Norway
Prior art keywords
amines
cell proliferation
tumor cell
prevent tumor
manufacture drugs
Prior art date
Application number
NO990401A
Other languages
English (en)
Other versions
NO322897B1 (no
NO990401D0 (no
Inventor
Jean-Claude Breliere
Pascual Ferrara
Christine Lebouteiller
Raymond Paul
Jorge Rosenfeld
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of NO990401D0 publication Critical patent/NO990401D0/no
Publication of NO990401L publication Critical patent/NO990401L/no
Publication of NO322897B1 publication Critical patent/NO322897B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20—Spiro-condensed ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/29—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
NO19990401A 1996-07-29 1999-01-28 Anvendelse av cis-N-sykloheksyl-N-etyl-[3-(3-klor-4-sykloheksylfenyl)allyl]amin for a fremstille en farmasoytisk blanding for a forhindre tumorcelleproliferasjon, samt farmasoytiske blandinger inneholdende slike NO322897B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9609531A FR2751645B1 (fr) 1996-07-29 1996-07-29 Amines pour la fabrication de medicaments destines a empecher la proliferation de cellules tumorales
PCT/FR1997/001409 WO1998004251A1 (fr) 1996-07-29 1997-07-28 Amines pour la fabrication de medicaments destines a empecher la proliferation de cellules tumorales

Publications (3)

Publication Number Publication Date
NO990401D0 NO990401D0 (no) 1999-01-28
NO990401L true NO990401L (no) 1999-03-25
NO322897B1 NO322897B1 (no) 2006-12-07

Family

ID=9494593

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19990401A NO322897B1 (no) 1996-07-29 1999-01-28 Anvendelse av cis-N-sykloheksyl-N-etyl-[3-(3-klor-4-sykloheksylfenyl)allyl]amin for a fremstille en farmasoytisk blanding for a forhindre tumorcelleproliferasjon, samt farmasoytiske blandinger inneholdende slike

Country Status (31)

Country Link
US (1) US6235791B1 (no)
EP (1) EP0917464B1 (no)
JP (1) JP3538431B2 (no)
KR (1) KR100315559B1 (no)
CN (1) CN1154483C (no)
AR (1) AR008090A1 (no)
AT (1) ATE266392T1 (no)
AU (1) AU735948B2 (no)
BR (1) BR9711606A (no)
CA (1) CA2261827C (no)
CZ (1) CZ294266B6 (no)
DE (1) DE69729099T2 (no)
DK (1) DK0917464T3 (no)
EE (1) EE03851B1 (no)
ES (1) ES2221061T3 (no)
FR (1) FR2751645B1 (no)
HU (1) HU224346B1 (no)
ID (1) ID17707A (no)
IL (1) IL127922A (no)
IS (1) IS2049B (no)
MY (1) MY120426A (no)
NO (1) NO322897B1 (no)
NZ (1) NZ333957A (no)
PT (1) PT917464E (no)
RU (1) RU2176502C2 (no)
SI (1) SI0917464T1 (no)
SK (1) SK285344B6 (no)
TR (1) TR199900161T2 (no)
UA (1) UA61080C2 (no)
WO (1) WO1998004251A1 (no)
ZA (1) ZA976697B (no)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2143403B1 (es) * 1998-03-13 2001-01-01 Consejo Superior Investigacion Derivados de ciclopropenilaminas como agentes anticancerosos.
GB9814036D0 (en) 1998-06-29 1998-08-26 Univ Dundee Materials and methods relating to the induction of apoptosis in target cells
FR2794742B1 (fr) * 1999-06-11 2005-06-03 Sanofi Synthelabo Nouveaux derives du benzene, un procede pour leur preparation et les compositions pharmaceutiques les contenant
FR2795724B1 (fr) * 1999-07-02 2002-12-13 Sanofi Synthelabo Nouveaux derives du benzene, un procede pour leur preparation et les compositions pharmaceutiques les contenant
FR2803593B1 (fr) * 2000-01-06 2002-02-15 Sanofi Synthelabo Nouvelles tetrahydropyridines, procede pour leur preparation et compositions pharmaceutiques les contenant
JP2005500392A (ja) * 2001-08-23 2005-01-06 バイエル・クロップサイエンス・ソシエテ・アノニム 置換されたプロパルギルアミン
FR2887454B1 (fr) * 2005-06-28 2009-06-05 Sanofi Aventis Sa Combinaisons antitumorales contenant des derives du taxane et des sigma ligands
WO2007150010A2 (en) 2006-06-23 2007-12-27 Abbott Laboratories Cyclopropyl amine derivatives as histamin h3 receptor modulators
US9108948B2 (en) * 2006-06-23 2015-08-18 Abbvie Inc. Cyclopropyl amine derivatives
AU2008226947B2 (en) 2007-03-08 2014-07-17 The Board Of Trustees Of The Leland Stanford Junior University Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof
CN102209541B (zh) 2008-09-08 2016-05-18 小利兰·斯坦福大学托管委员会 醛脱氢酶活性调节剂和其使用方法
US8389522B2 (en) 2008-10-28 2013-03-05 The Board Of Trustees Of The Leland Stanford Junior University Modulators of aldehyde dehydrogenase and methods of use thereof
US9186353B2 (en) 2009-04-27 2015-11-17 Abbvie Inc. Treatment of osteoarthritis pain
US8853390B2 (en) 2010-09-16 2014-10-07 Abbvie Inc. Processes for preparing 1,2-substituted cyclopropyl derivatives
US10457659B2 (en) 2011-04-29 2019-10-29 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
RU2015106915A (ru) * 2012-08-01 2016-09-20 Мерк Шарп И Доум Корп. МОДУЛЯТОРЫ α7 НИКОТИНОВОГО АЦЕТИЛХОЛИНОВОГО РЕЦЕПТОРА И ИХ ПРИМЕНЕНИЕ
JP6410790B2 (ja) 2013-03-14 2018-10-24 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー ミトコンドリアアルデヒドデヒドロゲナーゼ−２調節因子およびその使用方法
GEP20207149B (en) 2016-03-22 2020-09-10 Merck Sharp & Dohme Allosteric modulators of nicotinic acetylcholine receptors
WO2022058533A1 (en) 2020-09-17 2022-03-24 Meletios Therapeutics Compounds for treating virus infections

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3674832A (en) * 1968-08-22 1972-07-04 Schering Corp Cyclopropane carboxylic acid derivatives
FR2132547A1 (en) * 1971-04-08 1972-11-24 Clin Byla Ets Substd phenyl alkyl or alkenyl amides - useful as analgesics and antiinflammatories
GB1475314A (en) * 1973-11-02 1977-06-01 Cm Ind Phenyl-propylamine derivatives
US4104383A (en) 1973-11-02 1978-08-01 C M Industries Derivatives of phenylpropenylamine
IT1113391B (it) 1979-05-09 1986-01-20 Maggioni Farma Derivati fenilcicloesanici ad attivita' antidepressiva
US4537902A (en) * 1979-06-11 1985-08-27 Merck & Co., Inc. 4-Substituted-3-hydroxy-3-pyrroline-2,5-dione inhibitors of glycolic acid oxidase
FR2641276B1 (fr) * 1988-12-30 1991-07-12 Sanofi Sa Derives du benzene, leur preparation et les compositions pharmaceutiques en contenant
JP2814694B2 (ja) 1989-07-21 1998-10-27 セイコーエプソン株式会社 識別コード読み書き構造及びその装置及びその方法
FR2663328B1 (fr) * 1990-06-14 1994-08-05 Sanofi Sa Derives d'hexahydroazepines, un procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2694287B1 (fr) * 1992-07-31 1994-09-16 Jouveinal Inst Rech Nouvelles cycloalkylalkylamines ligands aux récepteurs sigma, leur procédé de préparation et leur application en thérapeutique.
US5849760A (en) * 1993-12-09 1998-12-15 Institut De Recherche Jouveinal 2-(arylalkenyl)azacycloalkane derivatives as ligands for sigma receptors
FR2724656B1 (fr) * 1994-09-15 1996-12-13 Adir Nouveaux derives du benzopyranne, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2725445B1 (fr) * 1994-10-10 1996-10-31 Adir Nouveaux derives a structure 1-arylalkenyl 4-aryl alkyl piperazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US5919934A (en) * 1997-02-19 1999-07-06 The George Washington University Compounds, compositions, and methods for cancer imaging and therapy

Also Published As

Publication number Publication date
EP0917464B1 (fr) 2004-05-12
NO322897B1 (no) 2006-12-07
FR2751645A1 (fr) 1998-01-30
WO1998004251A1 (fr) 1998-02-05
SK285344B6 (sk) 2006-11-03
PT917464E (pt) 2004-08-31
ID17707A (id) 1998-01-22
HU224346B1 (hu) 2005-08-29
CN1226825A (zh) 1999-08-25
DK0917464T3 (da) 2004-08-16
DE69729099D1 (de) 2004-06-17
MY120426A (en) 2005-10-31
TR199900161T2 (xx) 1999-04-21
US6235791B1 (en) 2001-05-22
UA61080C2 (uk) 2003-11-17
HUP9902806A3 (en) 2000-12-28
CZ294266B6 (cs) 2004-11-10
IS4946A (is) 1999-01-19
AR008090A1 (es) 1999-12-09
AU735948B2 (en) 2001-07-19
KR100315559B1 (ko) 2001-12-12
CZ24299A3 (cs) 1999-05-12
EP0917464A1 (fr) 1999-05-26
AU3855197A (en) 1998-02-20
IL127922A (en) 2003-11-23
EE9900029A (et) 1999-08-16
ZA976697B (en) 1998-02-10
CN1154483C (zh) 2004-06-23
RU2176502C2 (ru) 2001-12-10
ES2221061T3 (es) 2004-12-16
HU9902806A (en) 2000-04-28
FR2751645B1 (fr) 1998-12-24
EE03851B1 (et) 2002-10-15
CA2261827C (fr) 2004-10-26
KR20000029629A (ko) 2000-05-25
NZ333957A (en) 2000-09-29
SI0917464T1 (en) 2004-12-31
DE69729099T2 (de) 2005-05-12
IS2049B (is) 2005-09-15
SK7999A3 (en) 2000-01-18
ATE266392T1 (de) 2004-05-15
NO990401D0 (no) 1999-01-28
IL127922A0 (en) 1999-11-30
JP3538431B2 (ja) 2004-06-14
JP2000500782A (ja) 2000-01-25
BR9711606A (pt) 1999-08-24
CA2261827A1 (fr) 1998-02-05

Similar Documents

Publication Publication Date Title
NO990401L (no) Anvendelse av aminer for Õ fremstille legemidler for Õ forhindre tumorcelleproliferasjon
NO990433D0 (no) Nye forbindelser og blandinger for behandling av sykdommer i forbindelse med tryptase-aktivitet
DK0944616T3 (da) Bicykliske arylcarboxamider og deres terapeutiske anvendelse
ID18679A (id) Penggunaan terapi lanjutan
BR9711296A (pt) Composto processo terap-utico para inibir o crescimento de c-lulas de c ncer e composi-Æo farmac-utica
NO981789D0 (no) FremgangsmÕte for Õ bekrefte plasseringen av en array av detektorer
NO20015738D0 (no) Terapeutisk bruk av melatonin
DE69802692D1 (de) Derivate der chinoloncarbonsäure
NO991292D0 (no) Anvendelse av benzopyranoler for Õ behandle nevrologiske forstyrrelser
IS4532A (is) Notkun Melatóníns til meðferðar lyfjafíkla
DK0879054T3 (da) Anvendelse af pyrrolidionderivater til fremstilling af medikamenter til behandling af narkotikamisbrug
NO20001894D0 (no) Anvendelse av TNF-antagonister som medikamenter for behandling av septiske sykdommer
NO20010828L (no) Tidsforskyvningsteknikk for Õ øke kapasiteten i et kommunikasjonssystem av kategori CDMA
PT830344E (pt) Derivados de benzimidazole 2-substituido como inibidores da proliferacao de celulas musculares lisas
ID27014A (id) Metode yang lebih baik untuk pembuatan turunan-turunan norbenzomorfana yang bermanfaat secara farmasi
DK236489D0 (da) Anvendelse af diazepinoner til terapeutisk behandling af mikrokredsloebsforstyrrelser
DK0900078T3 (da) Anvendelse af benzonaphthalenderivater til fremstilling af lægemidler til behandling af sygdomme i nervesystemet
UA2U (uk) Конструкція накладної кишені
FI981139A0 (fi) Normobarisen hypoksian käyttö terapeuttisesti
NO962740D0 (no) Legemiddel til undertrykkelse av opium-avhengihet
ES293072Y (es) Nuevo parche terapeutico
FI991138A0 (fi) Normobarisen hypoksian käyttö terapeuttisesti
ATE338541T1 (de) Labdan-enthaltende arzneiformulierungen zur behandlung von tumoren oder leukämien
PT934307E (pt) Compostos azabicíclicos substituídos e sua utilização como inibidores da produção de tnf e da fosfodiesterase do amp cíclico

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees